← The record

Amino Acid Formula With Vitamins And Minerals, Without Phenylalanine And Tyrosine, Supplemented With Arachidonic Acid And Docosahexaenoic Acid

Recommended · restricted MetabolicRestrictedNot applicable line 💬 consumer voice

Dietary management of tyrosinaemia (TYR), primarily in infants and young children from 6 months to 5 years of age.

1
Submissions
2023–23
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Mar 2023
    Recommended · restricted

    vs TYR gel, TYR Anamix infant, TYR Anamix Junior

  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended the General Schedule Restricted Benefit listing of amino acid formula with vitamins and minerals, without phenylalanine and tyrosine and supplemented with arachidonic acid and docosahexaenoic acid (TYR explore5), for the dietary management of tyrosinaemia (TYR) under the same circumstances as TYR gel, except with a maximum quantity of 8 cartons rather than 4 cartons to provide the same number of grams of PE.PSD · Mar 2023
7.2 The PBAC considered that TYR explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (TYR gel, TYR Anamix infant or TYR Anamix Junior), at an equivalent price per gram of PE.PSD · Mar 2023
Economic analysis
5.9 The submission presented a cost-minimisation analysis of TYR explore5 compared with TYR gel, based on the same price per gram of PE of $1.33 at the approved ex- manufacturer price (AEMP) (Table 2).PSD · Mar 2023
Clinical claim
5.6 The submission claimed non-inferior comparative effectiveness and non-inferior comparative safety of TYR explore5 compared with TYR gel. The submission provided a comparison of the nutritional profile of TYR explore5 with TYR gel presented as Table 1.PSD · Mar 2023
5.7 The PBAC advised TYR explore5 is expected to provide a non-inferior clinical benefit for the management of TYR compared to the comparators identified.PSD · Mar 2023

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated by design.

The PBAC considered that TYR explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (TYR gel, TYR Anamix infant or TYR Anamix Junior), at an equivalent price per gram of PE. PBAC · 2023
Price cut / RSA needed

Decision context

PopulationInfants and young children from 6 months to 5 years of age requiring dietary management of tyrosinaemia.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2023 Recommended · restricted TYR gel, TYR Anamix infant, TYR Anamix Junior Cost-minimisation · Cost-minimisation

Consumer voice

Mar 2023

No consumer comments were received for this item.

The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD

Similar precedents

By decision profile